Literature DB >> 7104154

Abrupt withdrawal of pindolol or metoprolol after chronic therapy.

E Szécsi, S Kohlschütter, W Schiess, E Lang.   

Abstract

1 In an open controlled study a group of 18 healthy volunteers received either pindolol 10 mg three times daily or metoprolol 100 mg three times daily for 4 weeks. Before treatment, and after abrupt withdrawal the resting heart rate, the blood pressure, the exercise heart rate and the isoprenaline CD25 (dose of isoprenaline to increase the heart rate of 25 beats/min) were determined. Heart rates were continuously monitored by an ECG-coupled computer. The CD25 values were calculated by an off line computer procedure from the on line recorded data. 2 After metoprolol we found 6 out of 12 patients with a CD25 below baseline, in one case with a corresponding increase in heart rate during exercise. After pindolol we observed a CD25 below baseline only in one case with no corresponding reaction in the exercise test. In both groups we observed a reactive increase in resting heart rate and systolic blood pressure around day 5 after withdrawal. 3 We conclude that abrupt withdrawal of metoprolol in contrast to pindolol is associated with a higher risk of developing beta-adrenergic receptor hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104154      PMCID: PMC1402172          DOI: 10.1111/j.1365-2125.1982.tb01940.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Editorial: Propranolol withdrawal.

Authors:  D G Shand
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

2.  Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin.

Authors:  O Lederballe Pedersen; E Mikkelsen; J Lanng Nielsen; N J Christensen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

3.  Withdrawal of propranolol and myocardial infarction.

Authors:  R Slome
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

4.  A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol.

Authors:  C R Cleaveland; R E Rangno; D G Shand
Journal:  Arch Intern Med       Date:  1972-07

5.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.

Authors:  R R Miller; H G Olson; E A Amsterdam; D T Mason
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

6.  Beta-blocker withdrawal syndrome.

Authors:  P J Ross; M J Lewis; A H Henderson
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

7.  Beta-blocker withdrawal syndrome?

Authors:  T Meinertz; H Just; W Kasper; F Kersting; K H Breuing
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

8.  Beta-blocker withdrawal syndrome?

Authors:  B O Kristensen
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

9.  Propranolol withdrawal syndrome - why?

Authors:  D G Shand; A J Wood
Journal:  Circulation       Date:  1978-08       Impact factor: 29.690

10.  Mechanism of propranolol withdrawal phenomena.

Authors:  S Nattel; R E Rangno; G Van Loon
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

View more
  8 in total

1.  Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant?

Authors:  D G McDevitt
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

2.  Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study.

Authors:  Donald Redelmeier; Damon Scales; Alexander Kopp
Journal:  BMJ       Date:  2005-10-06

Review 3.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  The role of endogenous noradrenaline in the beta-blocker withdrawal phenomenon--studies with cultured heart cells.

Authors:  C Reithmann; A Thomschke; K Werdan
Journal:  Klin Wochenschr       Date:  1987-04-01

5.  Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.

Authors:  R J Walden; B Tomlinson; B Graham; J B Liu; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

6.  beta-Adrenoceptor hypersensitivity after stopping oxprenolol: discrepant findings not attributable to methodology.

Authors:  H Singh; A Rimmer; M J Lewis; A H Henderson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

7.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

Review 8.  Antihypertensive withdrawal for the prevention of cognitive decline.

Authors:  Susan Jongstra; Jennifer K Harrison; Terry J Quinn; Edo Richard
Journal:  Cochrane Database Syst Rev       Date:  2016-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.